Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

Hair loss treatments, including finasteride and RU58841, with humorous speculation about the cause of death for an ancient mummy that still had hair.

The conversation humorously discusses two resilient hair strands that resist DHT, with mentions of minoxidil and finasteride as ineffective treatments. Users joke about cloning the hairs and the mystery of baldness.

The conversation discusses feelings of despair and low self-worth due to hair loss and other perceived physical shortcomings. The user expresses a lack of motivation and struggles with societal expectations, despite trying various self-improvement methods.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

First people receive Pyrilutamide on March 19th, 2022 for hair loss treatment. Users discuss obtaining the drug, its patent, and potential group buys.

A 12-year-old diagnosed with alopecia shares their experience and current treatments, including Dermovate, an unnamed cream, and liquid iron. The community offers support and encouragement.

The post discusses a new hair loss treatment involving an improved pyri formula that has shown promising results, including thicker hair and a restored hairline, with minimal side effects. The author seeks investors to collaborate with Kintor or acquire the pyri patent, offering equity rewards and complimentary samples for verification.

Female considering adding topical anti-androgen, seeks advice on RU58841 or pyrilutamid's binding affinity compared to spironolactone.

User asks about Pyrilutamide release in Europe, specifically Germany, and considers importing it from China. No specific treatments mentioned.

The user is experiencing increased hair loss and was diagnosed with male pattern baldness. They are considering using oral or topical finasteride to manage the condition and are contemplating cutting their hair short.

A user experienced a loss of libido and anhedonia after severe dietary restriction while on Finasteride and Minoxidil for hair loss. They are considering reducing the Finasteride dose or taking a break to see if symptoms improve.

User hoodoomoovoo discusses their interest in stem cell research and its potential for hair loss treatment. They share links to studies and mention ongoing trials, expressing optimism for a future solution to hair loss.

OP is pausing hair loss treatments to focus on mental health due to anxiety and side effects from RU58841. They plan to try topical finasteride and minoxidil after recovering from pneumonia.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

Some people have side effects from finasteride and dutasteride due to hormonal predisposition, especially if DHT dominant. Alternatives like RU58841, Pyrilutamide, and Breezula are suggested to target scalp androgen receptors without altering overall hormones.

A user with scalp psoriasis and hair loss is hesitant to use topical minoxidil and finasteride due to concerns about psoriasis and potential side effects. They are considering alternatives like pumpkin seed and saw palmetto.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

Pyrilutamide is being discussed as a potential hair loss treatment, but opinions are mixed, with some users skeptical about its effectiveness and the company's credibility. Some users report combining pyrilutamide with other treatments like dutasteride and microneedling, noting improvements, while others remain doubtful.

PP405 is likely a scam, with concerns about its legitimacy and safety, as it may cause unintended tissue growth. Users suggest sticking to known treatments like finasteride and minoxidil.

Many users report negative experiences with Dutasteride, claiming it doesn't work as effectively as Finasteride for hair loss, despite some defending its efficacy. The conversation highlights skepticism about Dutasteride's effectiveness, with some users experiencing continued hair loss or no regrowth, while others see positive results.

Microneedling with verteporfin for hair loss. Users discuss its potential effectiveness.

Clascoterone 5% solution is not yet commercially available, with only the 1% solution currently sold for acne. Users discuss the potential of Clascoterone as a hair loss treatment, comparing it to other anti-androgens like RU58841 and Eucapil.

Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.

The conversation humorously discusses using semen as a topical treatment for hair growth, with users joking about its effectiveness and comparing it to other treatments like finasteride. The tone is light-hearted and sarcastic, with no serious endorsement of the method.

User tired of hair loss treatments, considers shaving head. Others suggest happiness matters most, ignore negativity.

Hair loss without a white bulb may indicate mechanical damage, anagen effluvium, alopecia areata, or traction alopecia. Seeking a specialist is recommended, but access can be difficult in smaller areas.

The conversation is about the potential risk of permanent hair loss from PRP (platelet rich plasma) treatments and whether PRF (platelet rich fibrin) carries the same risk. The user is seeking information on this topic.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

A young female diagnosed with Lichen planopilaris (LPP) experienced years of misdiagnosis and ineffective treatments, including a hair transplant and other procedures. She is considering litigation due to the misdiagnosis and has learned that LPP is chronic, hair loss can be stopped with ongoing medication, but lost hair cannot regrow.